Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

NCT03566017 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: pegunigalsidase alfa

Sponsor

Chiesi Farmaceutici S.p.A.